frontier models
The Target Finder Looks Where No Drug Has Looked
OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.
Summary
OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.
OPTAR excludes proteins already tied to a disease or existing drugs, scores indirect disease relevance through interaction networks, and checks AlphaFold structures for candidate pockets. In liver-cancer data it prioritized three proteins whose knockdown reduced cell viability and migration. Those cell experiments validate targets for further study, not medicines or patient benefit.
Why it matters
OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.
Limits and context
- Those cell experiments validate targets for further study, not medicines or patient benefit.
Key claims
OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.
Qualification: Those cell experiments validate targets for further study, not medicines or patient benefit.
Evidence: source-2026-07-18-011
Sources
- CAS via Newswise: OPTAR first-in-class targetsChinese Academy of Sciences via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.